Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics

揭示蝙蝠针对人畜共患病毒的体液免疫反应,以指导下一代疗法的设计

基本信息

  • 批准号:
    10240475
  • 负责人:
  • 金额:
    $ 108.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Cross-species transmission of pathogens is a major threat to public health worldwide and accounts for 75% of emerging human infectious diseases. Bats act as asymptomatic reservoir hosts for numerous zoonotic viruses, that are lethal in humans and for which no vaccines or specific therapeutics exist, indicating that the chiropteran immune system can control these viruses. Although there has been a recent growing interest in the peculiarities of bat innate immunity, their humoral immune response remains unexplored at the molecular level despite its known participation to fighting off pathogens. Previous studies revealed unusually fast bat B cell proliferation, compared to other mammals, and an exceptional immunoglobulin combinatorial diversity, suggesting a possible way these mammals successfully cope with an astounding diversity of viruses. We propose that the long co-evolution of bats with viruses could have led to the presence of highly specific immunoglobulin variable heavy chain segments playing a role in successfully controlling pathogens and that bat antibodies represent an untapped source of viral inhibitors. The proposed project will illuminate the role of bat humoral immunity in controlling pathogen infections, identify novel therapeutics against zoonotic viruses and guide the computational design of next-generation protein inhibitors of viral entry. This work will generate tools to combat emerging and re-emerging zoonotic viruses, including some pathogens that have not yet emerged or been discovered, and will be key to assist pandemic preparedness effort.
病原体的跨物种传播是对全球公共卫生的重大威胁

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Veesler其他文献

David Veesler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Veesler', 18)}}的其他基金

Project 1: Definition of the structural principles underlying broadly protective humoral immunity to coronaviruses
项目 1:冠状病毒广泛保护性体液免疫的结构原理的定义
  • 批准号:
    10425030
  • 财政年份:
    2022
  • 资助金额:
    $ 108.85万
  • 项目类别:
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics
揭示蝙蝠针对人畜共患病毒的体液免疫反应,以指导下一代疗法的设计
  • 批准号:
    10670195
  • 财政年份:
    2020
  • 资助金额:
    $ 108.85万
  • 项目类别:
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics
揭示蝙蝠针对人畜共患病毒的体液免疫反应,以指导下一代疗法的设计
  • 批准号:
    10462736
  • 财政年份:
    2020
  • 资助金额:
    $ 108.85万
  • 项目类别:
Structural Studies of Coronavirus Fusion Proteins
冠状病毒融合蛋白的结构研究
  • 批准号:
    9763906
  • 财政年份:
    2016
  • 资助金额:
    $ 108.85万
  • 项目类别:
Structural Studies of Coronavirus Fusion Proteins
冠状病毒融合蛋白的结构研究
  • 批准号:
    9759967
  • 财政年份:
    2016
  • 资助金额:
    $ 108.85万
  • 项目类别:
Structural Studies of Coronavirus Fusion Proteins
冠状病毒融合蛋白的结构研究
  • 批准号:
    9324294
  • 财政年份:
    2016
  • 资助金额:
    $ 108.85万
  • 项目类别:

相似海外基金

mRNA selective translational control required for B cell proliferation
B 细胞增殖所需的 mRNA 选择性翻译控制
  • 批准号:
    2757728
  • 财政年份:
    2022
  • 资助金额:
    $ 108.85万
  • 项目类别:
    Studentship
mRNA selective translational control required for B cell proliferation
B 细胞增殖所需的 mRNA 选择性翻译控制
  • 批准号:
    BB/X511547/1
  • 财政年份:
    2022
  • 资助金额:
    $ 108.85万
  • 项目类别:
    Training Grant
IL21, B-cell Proliferation and the Mechanism of Memory Formation
IL21、B 细胞增殖和记忆形成机制
  • 批准号:
    nhmrc : 1146617
  • 财政年份:
    2018
  • 资助金额:
    $ 108.85万
  • 项目类别:
    Project Grants
IL21, B-cell Proliferation and the Mechanism of Memory Formation
IL21、B 细胞增殖和记忆形成机制
  • 批准号:
    nhmrc : GNT1146617
  • 财政年份:
    2018
  • 资助金额:
    $ 108.85万
  • 项目类别:
    Project Grants
Elucidation of mechanisms regulating pancreatic b-cell proliferation using single-cell epigenomic analysis
使用单细胞表观基因组分析阐明调节胰腺 B 细胞增殖的机制
  • 批准号:
    17K19654
  • 财政年份:
    2017
  • 资助金额:
    $ 108.85万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Regulation of Normal and Pathogenic B Cell Proliferation by a c-Myc-initiated Transcription Factor Cascade
c-Myc 启动的转录因子级联对正常和致病性 B 细胞增殖的调节
  • 批准号:
    10229421
  • 财政年份:
    2017
  • 资助金额:
    $ 108.85万
  • 项目类别:
Regulation of Normal and Pathogenic B Cell Proliferation by a c-Myc-initiated Transcription Factor Cascade
c-Myc 启动的转录因子级联对正常和致病性 B 细胞增殖的调节
  • 批准号:
    9751756
  • 财政年份:
    2017
  • 资助金额:
    $ 108.85万
  • 项目类别:
Regulation of Normal and Pathogenic B Cell Proliferation by a c-Myc-initiated Transcription Factor Cascade
c-Myc 启动的转录因子级联对正常和致病性 B 细胞增殖的调节
  • 批准号:
    9457045
  • 财政年份:
    2017
  • 资助金额:
    $ 108.85万
  • 项目类别:
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
Epstein-Barr 病毒核抗原 2 和 LP 在 B 细胞增殖中的作用
  • 批准号:
    8634754
  • 财政年份:
    2013
  • 资助金额:
    $ 108.85万
  • 项目类别:
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
Epstein-Barr 病毒核抗原 2 和 LP 在 B 细胞增殖中的作用
  • 批准号:
    8820800
  • 财政年份:
    2013
  • 资助金额:
    $ 108.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了